Michael Link
Chemotherapy With Low-Dose Radiation for Pediatric Hodgkin's Disease
Contact Information
Stanford University School of Medicine 300 Pasteur Drive Stanford, CA 94305Brief
The main purpose of this protocol is to estimate the percentage of patients with intermediate risk Hodgkin's disease who will survive free of disease (Event-free survival) for three years after treatment with multi-agent chemotherapy (Stanford V) and low-dose, tailored-field radiation therapy. The hypothesis being studied is that this treatment will result in more than 80% of patients being alive and free of disease three years after starting treatment.
Recruiting Status:
RecruitingStanford Recruiting Status:
RecruitingCondition(s):
Intervention(s):
- Drug: Adriamycin, Vinblastine, Vincristine, Bleomycin
- Drug: Etoposide, Nitrogen Mustard, Prednisone
- Procedure: Radiotherapy
Phase:
Phase 3Eligibility
Ages Eligible for Study:
Any Age to 21 yearsGenders Eligible for Study:
Male and FemaleHealth of Volunteers:
People with the conditions listed in this trial can participate as controls.Key Inclusion Criteria:
- Patient is less than or equal to 21 years of age
- Patient has a confirmed diagnosis of previously untreated Hodgkin's disease
- Patient meets other requirements defined in the study guidelines
Key Exclusion Criteria:
- Patients with favorable risk features
- Patients with unfavorable risk features
- Patients who have received prior therapy for Hodgkin's disease.
Additional Study Details
Official Title:
Stanford V Chemotherapy With Low-Dose Tailored-Field Radiation Therapy for Intermediate Risk Pediatric Hodgkin's DiseaseAnticipated start date:
1/19/2007Lead Sponsor:
St. Jude ChildrenInvestigator(s):
Study Type:
InterventionalPurpose:
TreatmentAllocation:
Non-randomizedMasking:
OpenControl:
noneAssignment:
Single GroupEndpoints:
EfficacyPrimary Outcomes:
- Event free survival which is the time from treatment start to the time of the first failure (disease recurrence, second malignancy or death).
Total Number to be Enrolled:
82Total Number to be Enrolled at Stanford:
35More Information
Secondary ID(s):
- 97485
- HOD05
- NCT00352027
- PEDSHOD05
Locations & Contacts
Stanford Locations & Contacts:
Stanford University School of Medicine 300 Pasteur Drive Stanford, CA 94305Non-Stanford Locations:
The Stanford website does not have any locations outside of Stanford listed for this trial. You may want to check clinicaltrials.gov for posible additional locations.
This listing was last updated:
8/24/2009PLEASE NOTE:
Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers are provided for obtaining additional information on specific clinical research trials only. If you have specific questions which require clinical expertise, please call your primary care physician. If you do not have a primary care physician please feel free to call the SHC Physician Referral Service at (800) 756-9000 or send an email.
Help